Oxaliplatin is one of a group of drugs called alkylating agents, which is a type of chemotherapy. Oxaliplatin works by sticking to one of the cancer cell's DNA. strands. DNA is the genetic code that is in the nucleus of all animal and plant cells. Oxaliplatin is a platinum(II) coordination complex containing the 1,2-diaminocyclohexane DACH carrier ligand and an oxalate leaving group. In aqueous and biological media the oxalate dissociates and reactive platinum species form covalent adducts, predominantly at guanine N7 positions, producing intrastrand crosslinks that distort the DNA helix, interfere with replication and transcription, and activate cell death pathways. The bulky DACH ligand influences recognition and repair of the adduct relative to other platinum agents and contributes to activity in colorectal and other solid tumors. Oxaliplatin is administered intravenously, undergoes nonenzymatic biotransformation to short-lived reactive intermediates, exhibits substantial plasma protein binding, and is eliminated mainly via renal excretion. Clinically relevant toxicities include cumulative peripheral sensory neuropathy with characteristic cold sensitivity, myelosuppression, and gastrointestinal effects.
Parent: Oxaliplatin
Parent: Oxaliplatin
Parent: Oxaliplatin
Parent: Oxaliplatin
Parent: Oxaliplatin
Oxaliplatin drug substance and drug product specifications focus on control of related platinum species, ligand-derived impurities, oxalate-related hydrolysis products, residual solvents, and inorganic contaminants. Typical quality specifications in development and compendial monographs set limits for individual identified related substances in the low parts-per-thousand to parts-per-ten-thousand range, for example individual specified impurities commonly controlled at approximately 0.05 to 0.5% w/w and total related substances limited to around 1.0 to 2.0% w/w depending on qualification and toxicological assessment. Residual solvents are controlled per ICH Q3C with Class 2 and 3 solvents limited in ppm levels according to their classification, and heavy metal content and elemental impurities are managed per ICH Q3D limits. Specific impurity profiles include mono- and di-aquo platinum complexes, chloride-exchanged platinum species, partially hydrolyzed oxalate derivatives, DACH-containing degradation products, and process-related organic residues; each identified impurity is qualified and assigned acceptance criteria based on safety, stability, and regulatory guidance.
Oxaliplatin is used primarily in combination chemotherapy regimens for colorectal cancer, most commonly as part of FOLFOX with 5-fluorouracil and leucovorin; it is also applied in other solid tumor settings based on clinical judgement and evidence from trials.
Complete alopecia is less common with oxaliplatin than with some other cytotoxic agents, but hair thinning or partial hair loss can occur, especially when oxaliplatin is given in combination with other chemotherapy drugs that cause hair loss.
Success rates depend on indication, line of therapy, combination regimen, and patient factors; in first-line metastatic colorectal cancer trials, regimens containing oxaliplatin produced objective response rates and survival benefits compared with 5-fluorouracil alone, with response rates frequently reported in the range of several tens of percent. Individual prognosis should be discussed with an oncology team because outcomes vary widely.
Avoid exposure to cold, including cold foods and beverages, and abrupt temperature changes because these can trigger or worsen cold-induced neuropathy; avoid concurrent use of other neurotoxic agents unless supervised by your clinician; disclose all medications, supplements, and herbal products to your treating team; and follow guidance on contraception and pregnancy because of potential fetal risk.
